Pulmonx (NASDAQ:LUNG) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Pulmonx (NASDAQ:LUNG) from a hold rating to a sell rating in a report released on Saturday.

A number of other equities research analysts have also recently issued reports on LUNG. D. Boral Capital cut their price objective on shares of Pulmonx from $16.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, October 28th. Wells Fargo & Company lowered their price target on shares of Pulmonx from $6.00 to $3.00 and set an “equal weight” rating for the company in a research note on Friday, August 1st. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research report on Wednesday, October 8th. Piper Sandler cut Pulmonx from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $9.00 to $2.50 in a research note on Thursday, July 31st. Finally, Stifel Nicolaus decreased their price objective on Pulmonx from $16.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 31st. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.81.

Pulmonx Stock Up 1.0%

Shares of LUNG opened at $1.94 on Friday. Pulmonx has a 1 year low of $1.47 and a 1 year high of $9.37. The company has a debt-to-equity ratio of 0.54, a current ratio of 5.35 and a quick ratio of 4.63. The stock has a 50 day simple moving average of $1.71 and a two-hundred day simple moving average of $2.42. The firm has a market cap of $79.06 million, a P/E ratio of -1.36 and a beta of 0.44.

Hedge Funds Weigh In On Pulmonx

Hedge funds and other institutional investors have recently modified their holdings of the company. Corton Capital Inc. purchased a new stake in shares of Pulmonx during the second quarter worth about $32,000. R Squared Ltd bought a new position in Pulmonx during the 2nd quarter valued at approximately $41,000. Bank of Montreal Can purchased a new stake in Pulmonx in the 2nd quarter worth approximately $53,000. Perkins Capital Management Inc. grew its position in shares of Pulmonx by 110.0% in the 3rd quarter. Perkins Capital Management Inc. now owns 21,000 shares of the company’s stock worth $34,000 after buying an additional 11,000 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Pulmonx by 95.8% during the third quarter. SG Americas Securities LLC now owns 24,863 shares of the company’s stock valued at $40,000 after buying an additional 12,166 shares during the period. 91.04% of the stock is owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.